REG - AOTI, Inc. - Director Shareholding - Share Purchase

AotiAnnouncement

07/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250507:nRSG6503Ha&default-theme=true

RNS Number : 6503H  AOTI, Inc.  07 May 2025

7 May 2025

 

AOTI Inc.

(the "Company")

 

Director/PDMR Shareholding - Share purchase

 

The Company was informed on 6 May 2025 that Mr Douglas Lefort, Non-executive
Chaiman of the Company, bought a total of 31,094 common shares of $0.00001 in
the capital of the Company ("Common Shares") at 80 pence per share.

 

Following the purchase, Mr Lefort's beneficial holding (including that of his
spouse) and the total interest in the Company has increased to 1,482,715
Common Shares, representing approximately 1.39% of the Company's issued share
capital.

 

The below notification, made in accordance with Article 19 of the Market Abuse
Regulation (EU) 596/2014 as it forms part of domestic law by virtue of the
European Union (Withdrawal) Act 2018, provides further detail.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with
them

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Mr Douglas Lefort

 2    Reason for the notification

 a)   Position/status                                              Non-executive Chairman

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         AOTI Inc.

 b)   LEI                                                          213800ZGCNDSTWIRK687

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Common shares of $0.00001 each

      Identification code

                                                                   ISIN: US03690C1027
 b)   Nature of the transaction                                    Purchase of Common Shares by Mr Lefort on 6 May 2025

 c)   Price(s) and volume(s)                                       Price(s)  Volume(s)

                                                                 80p       31,094

 d)   Aggregated information

      - Aggregated volume                                          NA

      - Price                                                      NA

 e)   Date of the transaction                                      6 May 2025

 f)   Place of the transaction                                     London Stock Exchange

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

NA

 

NA

e)

 

Date of the transaction

 

6 May 2025

f)

 

Place of the transaction

 

London Stock Exchange

 

For further information please contact:

 

 AOTI, INC.

 Dr. Mike Griffiths, Chief Executive Officer   +44 (0)20 3727 1000

 Jayesh Pankhania, Chief Financial Officer     ir@aotinc.net (mailto:ir@aotinc.net)

 Peel Hunt LLP (Nominated Adviser and Broker)

 Dr. Christopher Golden, James Steel           +44 (0)20 7418 8900

 FTI Consulting (Financial PR & IR)

 Ben Atwell, Simon Conway,                     +44 (0)20 3727 1000

 Natalie Garland-Collins, Alex Davis           AOTI@fticonsulting.com (mailto:AOTI@fticonsulting.com)

 

ABOUT AOTI, INC.

 

AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and
Galway, Ireland, providing innovative solutions to resolve severe and chronic
wounds worldwide. Its products reduce healthcare costs and improve the quality
of life for patients with these debilitating conditions. The Company's
patented non-invasive Topical Wound Oxygen (TWO(2)(®)) therapy has
demonstrated in differentiating, robust, double-blinded randomised controlled
trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the
recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88
per cent reduction in hospitalisations and 71 per cent reduction in
amputations over 12 months. TWO(2)(®) therapy can be administered by the
patient at home, improving access to care and enhancing treatment compliance.
TWO(2)(®) therapy has received regulatory clearance from the US (FDA), Europe
(CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products
Administration, Australia (TGA) and in Saudi Arabia. Also see www.aotinc.net
(http://www.aotinc.net)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUPUUCAUPAUAM